Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of remimazolam toluenesulfonate plus sufentanil vs propofol in painless endoscopic ultrasonography
ChiCTR2300069412Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Guizhou Medical University
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of remimazolam (2 arms), sponsored by Affiliated Hospital of Guizhou Medical University. Primary endpoint: Incidence of hypotension. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
remimazolam
Beyond the preview
Go deeper on ChiCTR2300069412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069412.